Today, the term MSC describes a class of cells that have historically been known as mesenchymal stem cells, mesenchymal stromal cells, and medicinal signaling cells, among other names. The clinical utility of MSCs is primarily attributed to their key biological properties, which include: [Read more…]
Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).
MCSs are multipotent progenitor cells capable of developing into a variety of cell types during human development, including adipocytes, chondrocytes, osteocytes, and cardiomyocytes. Population aging and an increasing prevalence of chronic disease are driving interest in MSC-based therapies. Over the past 150 years, the average human lifespan has doubled and continued increases in life-expectancy are expected. [Read more…]
Overland Park, KS – In a groundbreaking development, a recent peer-reviewed paper titled “Mesenchymal Stem Cell Extracellular Vesicles from Tissue-Mimetic System Enhance Epidermal Regeneration via Formation of Migratory Cell Sheets,” published on July 29, 2023, in the journal “Tissue Engineering and Regenerative Medicine,” offers open access to its findings. [Read more…]
Overland Park, KS – A groundbreaking study titled “Tailoring the Secretome Composition of Mesenchymal Stem Cells to Augment Specific Functions of Epidermal Regeneration: An In Vitro Diabetic Model,” conducted by, Jacob G. Hodge, Ph.D., introduces a pioneering strategy to revolutionize epidermal regeneration using the secretome of mesenchymal stem cells (MSCs) utilizing Ronawk’s Bio-Blocks™. Published in June 2023 in the journal
“Frontiers in Medical Technology” and available through open access, the study unveils a powerful solution for optimizing wound healing, particularly in a diabetic context. [Read more…]
Camarillo, CA (April 11, 2023) – PBS Biotech, an innovative, single-use bioreactor manufacturer and process development services provider, announces its collaboration with denovoMATRIX, a leading supplier of next-gen biomimetic coating technologies. By joining forces, PBS Biotech and denovoMATRIX seek to foster xeno-free expansion and scale-up of clinical-grade mesenchymal stromal cells (MSCs) and induced pluripotent stem cells (iPSCs) for use in allogeneic and autologous cell and gene therapies. The first outcome of this collaboration is a white paper presenting the advantages in MSC manufacturing that can be achieved using their cutting-edge technologies. [Read more…]